Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/03/21
End: 04/04/23
Due: 04/04/24
Phase: N/A
Priority: Normal
Start: 08/23/21
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 07/20/16
End: 01/31/18
Due: 01/31/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy | NCT03692312 | AMO Pharma Limited | user2@example.com | None | 2021-03-03 | 2023-04-04 | 2024-04-04 | - | - | 2025-07-14 |
| Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | NCT05004129 | AMO Pharma Limited | user2@example.com | None | 2021-08-23 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |
| Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy | NCT02858908 | AMO Pharma Limited | user2@example.com | None | 2016-07-20 | 2018-01-31 | 2019-01-31 | - | - | 2025-07-14 |